Precision medicine in diffuse large B-cell lymphoma: Integrating molecular biomarkers, targeted therapies, and prognostic tools

Table 4 Genomic differences between human immunodeficiency virus-positive and -negative diffuse large B-cell lymphoma

Gene/feature	HIV+ DLBCL	HIV- DLBCL	P value
TP53 mutation	More frequent, diverse	Less frequent	< 0.05
MYD88 mutation	Significantly reduced	Common (especially in MCD subtype)	< 0.05
CD79B mutation	Significantly reduced	Common	< 0.05
PIM1 mutation	Significantly reduced	Common	< 0.05
MYC mutation (SNV)	More frequent	Less frequent	< 0.05
LRP1B/TYK2 mutation	Higher frequency	Lower frequency	< 0.05
LymphGen ‘unclassified’ proportion	Higher	Lower	< 0.05

SNV: Single nucleotide variant; MCD: MYD88 (L265P)/CD79B-mutated subtype; LymphGen: A probabilistic classification tool for genetic subtypes of DLBCL.